Versono envisage a future where all complex vascular occlusions can be efficiently treated using endovascular therapies to alleviate pain, save limbs and save lives.

Versono is developing and commercialising a new technology platform for endovascular surgery that will focus initially on patients with Critical Limb Threatening Ischemia (CLTI), the most severe and advanced clinical manifestation of Peripheral Arterial Disease (PAD). Their mission is to enable endovascular treatment of Complex Chronic Total Occlusions in order to address poor patient outcomes, high amputation and high mortality rates associated with CLTI.